Italia markets open in 4 hours 23 minutes

Akari Therapeutics, Plc (AKTX)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,19000,0000 (0,00%)
Alla chiusura: 04:00PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,1900
Aperto1,2000
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno1,1700 - 1,2000
Intervallo di 52 settimane1,0780 - 5,5000
Volume3.802
Media Volume11.743
Capitalizzazione9,429M
Beta (5 anni mensile)0,96
Rapporto PE (ttm)N/D
EPS (ttm)-2,0400
Prossima data utili29 apr 2024 - 03 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A80,00
  • GlobeNewswire

    Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now

    MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 63rd Emerging Growth Conference on October 4th and 5th, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting

  • GlobeNewswire

    Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

    Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase 3 clinical trials in pediatric and adult HSCT-TMA and start PAS-nomacopan clinical trials in geographic atrophy (GA)Granted orphan drug designation from the European Commission for treatment in hematopoietic stem cell transplantation, adding to existing FDA Orphan Drug, Fast Track and Rare Pediatric Disease designationsThe company established a Boston U.S. headquarters office to support e

  • GlobeNewswire

    Akari Therapeutics to Present at Emerging Growth Conference

    BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Emerging Growth Conference being held October 4 and 5, 2023. President and CEO Rachelle Jacques will present an overview of the company and its lead asset nomacopan, a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), on Octobe